Table of Contents
1 Industry Outlook 10
1.1 Industry Overview 10
1.1.1 Industry Trends 11
1.1.2 R&D pipeline in pharmaceutical industry 11
1.2 Total addressable market 12
2 Report Outline 14
2.1 Report Scope 14
2.2 Report Summary 14
2.3 Research Methodology 15
2.4 Report Assumptions 15
3 Market Snapshot 17
3.1 Market Definition - Infoholic Research 17
3.2 Need of CRO 17
3.3 History of CRO 17
3.4 Segmented Addressable Market (SAM) 18
3.5 Trends of the pharma contract research organization market 18
3.6 Related Markets 19
3.6.1 Pharmaceutical Contract manufacturing organization market 19
3.6.2 Drug discovery outsourcing 20
4 Market Outlook 21
4.1 Funding Scenario 24
4.2 Process of Drug Development 25
4.3 Market segmentation 25
4.4 PEST Analysis 26
4.5 Porter 5(Five) Forces 28
5 Market Characteristics 29
5.1 DRO - Global pharma contract research organization Market Dynamics 29
5.1.1 Drivers 29
5.1.1.1 Upsurge in outsourcing of R&D activities 29
5.1.1.2 Rising number of clinical trials across the globe 30
5.1.2 Opportunities 31
5.1.2.1 Growth in the biopharmaceutical market 31
5.1.2.2 Increasing number of deals to develop new compounds for rare disease 31
5.1.3 Restraints 31
5.1.3.1 Quality issues related to services offered by CRO 31
5.1.3.2 Lack of trained professionals 32
5.2 DRO - Impact Analysis 33
5.3 Key Stakeholders 33
6 Service type: Market Size & Analysis 35
6.1 Overview 35
6.2 Discovery services 36
6.3 Preclinical study services 38
6.3.1 Pharmacokinetics/Pharmacodynamics 40
6.3.2 Toxicology testing 40
6.3.3 Others 41
6.4 Clinical study services 41
6.4.1 Phase I 43
6.4.2 Phase II 43
6.4.3 Phase III 43
6.4.4 Phase IV 43
6.5 Others 44
7 Therapeutic indication: Market Size & Analysis 45
7.1 Overview 45
7.2 Oncology 46
7.3 Respiratory disease 46
7.4 CNS disorder 46
7.5 Infectious disease 47
7.6 Cardiovascular disease 47
7.7 Immunological disorder 47
7.8 Diabetes 47
7.9 Others 48
8 Regions: Market Size and Analysis 49
8.1 Overview 49
8.2 North America 50
8.3 Europe 52
8.4 Asia Pacific 53
8.5 Rest of the World 55
9 Competitive Landscape 56
9.1 Overview 56
10 Vendor Profiles 59
10.1 Charles River Laboratories' Inc. 59
10.1.1 Overview 59
10.1.2 Charles River Laboratories' Inc.: Recent Developments 60
10.1.3 Business Units 62
10.1.4 Geographic Revenue 63
10.1.5 Business Focus 64
10.1.6 SWOT Analysis 65
10.1.7 Business Strategies 65
10.2 Laboratory Corporation of America Holdings (LABCORP) 66
10.2.1 Overview 66
10.2.2 Laboratory Corporation of America Holdings: Recent Developments 68
10.2.3 Business Units 70
10.2.4 Geographic Revenue 71
10.2.5 Business Focus 71
10.2.6 SWOT Analysis 72
10.2.7 Business Strategies 72
10.3 IQVIA HOLDINGS INC. 73
10.3.1 Overview 73
10.3.2 Business Units 76
10.3.3 Geographic Revenue 76
10.3.4 Business Focus 77
10.3.5 SWOT Analysis 78
10.3.6 Business Strategies 78
10.4 Pharmaceutical Product Development Inc 79
10.4.1 Overview 79
10.4.2 Business Focus 81
10.4.3 SWOT Analysis 81
10.4.4 Business Strategy 81
10.5 ICON PLC 82
10.5.1 Overview 82
10.5.2 Geographic Revenue 85
10.5.3 Business Focus 86
10.5.4 SWOT Analysis 86
10.5.5 Business Strategies 87
10.6 PAREXEL International Corporation 88
10.6.1 Overview 88
10.6.2 Business Units 90
10.6.3 Geographic Revenue 91
10.6.4 Business Focus 92
10.6.5 SWOT Analysis 93
10.6.6 Business Strategies 93
11 Companies to Watch for 95
11.1 PRA HEALTH SCIENCES' INC. 95
11.1.1 Overview 95
11.2 Syneos Health Inc 96
11.2.1 Overview 96
11.3 WuXi AppTec 99
11.3.1 Overview 99
11.4 Medpace Holdings' Inc. 100
11.4.1 Overview 100
11.5 SGS SA 101
11.5.1 Overview 101
11.6 Envigo 103
11.6.1 Overview 103
11.7 EPS INTERNATIONAL 105
11.7.1 Overview 105
11.8 EVOTEC AG 106
11.8.1 Overview 106
11.9 GenScript Biotech Corporation 110
11.9.1 Overview 110
11.10 Eurofins Scientific 111
11.10.1 Overview 111
Annexure 115
? Acronyms 115